Abstract: |
Imaging plays a vital role in assessing response to treatment following locoregional therapies (LRTs) for cancer as well as in determining the presence of residual cancer or recurrent disease on surveillance studies. Oncologic response to systemic cancer treatment is most frequently evaluated using cross-sectional imaging with treatment success typically determined by decreased tumor size and/or enhancement. The objective of this chapter is to describe the imaging features over time of normal, expected tumor response following energy-based ablation and transarterial embolization for select liver, pulmonary, renal, and prostate malignancies, as well as describing the findings of viable or recurrent tumor post-treatment. © Springer Nature Switzerland AG 2020. |